

## Press Release

Martinsried/Munich, October 6th, 2016

# **Thermosome appoints Dr. Ulrich Grau, Dr. Jochen Knolle and Dr. Franz-Robert Klingan to its advisory board**


Thermosome GmbH, an emerging biopharmaceutical company, today announces the appointment of Dr. Ulrich Grau, Dr. Jochen Knolle and Dr. Franz-Robert Klingan to its advisory board.

Dr. Ulrich Grau has more than 35 years experience in the biopharmaceutical industry spanning from basic R&D functions to executive positions in Pharma and Biotech companies in Germany and the US. Starting his career as a scientist at Hoechst and being one of the key inventors that led to the blockbuster insulin Lantus<sup>®</sup>, he spent almost two decades at Hoechst/Aventis in different functions, including SVP of late-stage global development. Thereafter, his roles included President R&D and member of the executive board of BASF Pharma/Knoll, which developed today's world best-selling drug Humira<sup>®</sup> as key pipeline project and was acquired by Abbott for \$6.9B in late 2000, Chief Scientific Officer of Enzon, Co-founder, President & CEO of LuxBiosciences, as well as EVP and Chief Operating Officer of Micromet, which was acquired by Amgen for \$1.2B in 2012. Currently, he serves as Chairman and Co-founder of i-novion, a private drug delivery company developing sustained release formulations of biologics, as member of the Supervisory Board of Affimed and Humabs Biomed, and as advisor to various biopharmaceutical companies.

Dr. Jochen Knolle's experience includes more than three decades in the pharmaceutical industry and encompasses every aspect of drug discovery, development and registration. He spent two decades in the central pharmaceutical research unit of Hoechst and was named as one of the key inventors of Icatibant<sup>®</sup>, a first-in-class Bradykinin-2 receptor antagonist, and Quinapril<sup>®</sup>, an Angiotensin Converting Enzyme (ACE) inhibitor. In 1998, he joined Axys Pharmaceuticals as Vice President Medicinal Chemistry and Structural Biology and became Jerini's Chief Scientific Officer in 2001. At Jerini, he in-licensed Icatibant (Firazyr<sup>®</sup>) and developed it for the rare disease hereditary angioedema until EU approval in 2008, which led to the acquisition of Jerini by Shire for \$512M. Since then, Jochen serves as Consultant to biopharmaceutical companies, as Senior Advisor to TVM Capital, as well as in the (scientific) advisory boards of Charité CRO, Anchor Therapeutics, Noxxon Pharma, Bicycle Therapeutics, and OMEICOS Therapeutics. Jochen co-founded 3B Pharmaceuticals, Kosa Pharma and Pharvaris, where he currently serves as Managing Director.

Dr. Franz-Robert Klingan is a partner at Bain & Company. He is responsible for Bain's services for healthcare investors across EMEA and is a leader in Bain's Healthcare and Private Equity practices. He has more than 20 years of industry and management consulting experience on both sides of the Atlantic, advising major corporate and private equity clients on M&A, integration and performance improvement, as well as working with multinational client teams and investors to develop new strategies primarily in the healthcare, biopharmaceuticals, medical technologies and related industries. Prior to joining Bain & Company, he was active in varying roles in biotech technology transfer, plant management and project & alliance management in the pharmaceutical industry, and started his career at Hoechst.

Thermosome's managing director, Dr. Pascal Schweizer, comments: "We are happy to appoint such a high-profile advisory board comprising experienced senior executives from the biopharmaceutical industry, each with a track record of several decades in various functions across the industry's value chain. Most notably, our board comprises in-depth experience in drug development, including several successfully approved drugs. We look forward to our board members' contributions to translate our highly promising technology into a successful business."

**Media contact**

Thermosome GmbH  
Dr. Pascal Schweizer  
Managing Director & Chief Financial Officer (CFO)  
+49 (0)89 7167760-31  
[media@thermosome.com](mailto:media@thermosome.com)

**About Thermosome**

Thermosome<sup>®</sup> is an emerging biopharmaceutical company leveraging its proprietary drug delivery technology platform to create products with improved therapeutic index. Through its TSL technology, drug-loaded nanocarriers – so-called Thermosomes – can be created which after intravenous infusion release their content locally upon the influence of mild heat of 40-42°C achieved by various clinically established targeted heating techniques such as microwave or ultrasound. With our Thermosomes, up to 15 fold higher local drug concentrations can be reached while simultaneously markedly reducing systemic exposure and potentially associated side effects. Thermosome's lead candidate, a formulation of a potent, but highly toxic chemotherapeutic agent, is currently in pre-clinical development. For more information, visit [www.thermosome.com](http://www.thermosome.com).

*This communication contains certain forward-looking statements concerning Thermosome. The forward-looking statements contained herein represent the judgment of Thermosome as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. Thermosome does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.*